BIOMARKERS FOR DEMENTIA DIAGNOSIS

VolverGo back

Resultados 61 results. LastUpdate Updated on 19/08/2022 [13:12:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Page1/3 nextPage   results/page


A BIOMARKER FOR ALZHEIMER'S DISEASE USING BLOOD SAMPLES FROM CLINICALLY DIAGNOSED ALZHEIMER'S DISEASE SUBJECTS

Publication No.: US2022260595A1 18/08/2022

Applicant:

TODOS MEDICAL LTD [IL]

KR_20220034769_PA

Absstract of: US2022260595A1

The current invention discloses a method for diagnosing Alzheimer disease by using biomarkers, and multivariate analysis which gives a more reliable, minimally- or non-invasive method of detection. The invention discloses simultaneous detection of CD69 protein in mitogenic lymphocytes, tau and phosphorylated tau proteins, and amyloid-β peptides in cerebrospinal fluid, which can replace or supplement conventional methods of detection of Alzheimer's disease such as cognitive testing and amyloid-positron emission tomography.

traducir

BIOMARKERS FOR DIAGNOSING ALZHEIMER'S DISEASE

Publication No.: US2022260559A1 18/08/2022

Applicant:

SEER INC [US]

Absstract of: US2022260559A1

Disclosed herein are compositions, systems, and methods for identifying neurological diseases from biological sample analysis. A biological sample from a subject may be contacted to a particle to form a biomolecule corona, which may contain a subset of biomolecules from the biological sample and which can have utility for diagnosing a neurological disease state. Further disclosed herein are machine learning algorithms and trained classifiers for distinguishing neurological disease states based on biological data.

traducir

METHOD OF DETECTING COGNITIVE IMPAIRMENT

Publication No.: US2022260591A1 18/08/2022

Applicant:

CEDARS SINAI MEDICAL CENTER [US]

Absstract of: US2022260591A1

The present invention describes a method for the detection, diagnosis and monitoring of cognitive impairment and Alzheimer's disease. The method involves the detection of pericyte loss and deficiency in PDGFRβ, alone or in combination with retinal vascular Aβ deposits. The method also involves detecting an alteration in blood-retinal barrier (BRB) cell tight junction.

traducir

TARGETS AND METHODS OF DIAGNOSING, MONITORING AND TREATING FRONTOTEMPORAL DEMENTIA

Publication No.: US2022260593A1 18/08/2022

Applicant:

SIERKS MICHAEL [US]
WILLIAMS STEPHANIE [US]

WO_2020252394_A2

Absstract of: US2022260593A1

Disclosed herein are antibodies, antibody fragments, binding agents, and compositions that specifically recognize protein variant biomarkers associated with frontotemporal dementia, kits and methods of use, including diagnosing, monitoring and treating frontotemporal dementia.

traducir

METHODS OF TREATING EPILEPSY

Publication No.: US2022257572A1 18/08/2022

Applicant:

UNIV YALE [US]

WO_2020168096_A1

Absstract of: US2022257572A1

In various aspects and embodiments the invention provides a method of treating epilepsy in a subject in need thereof, the method comprising providing to the subject an effective amount of an FLNA modulator. In various embodiments, the FLNA modulator is PTI-125 or kartogenin. In various embodiments, the epilepsy is epilepsy associated with focal cortical dysplasia (FCD) type II or tuberous sclerosis complex (TSC).

traducir

COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE

Publication No.: US2022257612A1 18/08/2022

Applicant:

KADDURAH DAOUK RIMA F [US]
MAHMOUDIANDEHKORDI SIAMAK [US]
VAN DUIJIN CORNELIA [GB]
AHMAD SHAHZAD [NL]
SAYKIN ANDREW J [US]
NHO KWANGSIK [US]
BAILLIE REBECCA [US]
HAN XIANLIN [US]
UNIV DUKE [US]
UNIV OXFORD [GB]
ERASMUS MEDICAL CENTER [NL]
INDIANA UNIV SCHOOL OF MEDICINE [US]
UNIV OF TEXAS [US]

WO_2021016551_A1

Absstract of: US2022257612A1

Described herein are methods for identifying or diagnosing Alzheimer's disease or poor cognition in a subject or population of subjects by analyzing biomarkers. In one aspect, the biomarkers comprise liver function enzymes or metabolites including alanine aminotransferase (ALT), aspartate aminotransferase (AST), ratio of ALT to AST, alkaline phosphatase, albumin, bilirubin, cholesterol and cholesterol metabolites, amino acids, phospholipids, bile acids, or other metabolites. In another aspect, the biomarkers comprise alanine aminotransferase (ALT), aspartate aminotransferase (AST), or the ratio of ALT to AST levels. In another aspect, the marker comprises the genotype of the ALT or AST enzymes.

traducir

NON-HUMAN ALZHEIMER'S DISEASE MODEL ANIMAL AND METHOD FOR PRODUCING SAME

Publication No.: EP4043568A1 17/08/2022

Applicant:

ALZMED INC [JP]

CN_114727591_PA

Absstract of: EP4043568A1

The current Alzheimer's disease model mouse, developed by manipulating the expression of a gene directly related to distinctive pathology that is specific to the disease, such as acceleration of amyloid plaque deposition, is a model of a preclinical state, or of a pathology that is fundamentally different from human Alzheimer's disease. In view of the current state described above, the present invention addresses the problem of developing a non-human transgenic animal in which Alzheimer's pathology is more accurately reflected, and thereby elucidating a disease mechanism or contributing to drug discovery. In the present invention, by heterozygous knockout of the drebrin gene of a non-human Alzheimer's disease model animal used as a base, senescence risk can be imparted to the conventional non-human Alzheimer's disease model animal. Alzheimer's pathology is more accurately reflected in this non-human Alzheimer's disease model animal.

traducir

BLOOD INDICATORS OF ALZHEIMER'S DISEASE

Publication No.: US2022252620A1 11/08/2022

Applicant:

THE INST FOR ETHNOMEDICINE DBA BRAIN CHEMISTRY LABS [US]

WO_2022168006_A1

Absstract of: US2022252620A1

Presented herein are methods of identifying a subject who has, or is at risk of developing Alzheimer's disease comprising determining a presence or amount of 2-aminoethyl dihydrogen phosphate or taurine in the blood, or a blood product, obtained from the subject. Also presented herein are method of preventing, treating or delaying the onset of Alzheimer's disease.

traducir

DIAGNOSTIC METHOD BASED ON LARGE SCALE IDENTIFICATION OF POST-TRANSLATIONAL MODIFICATION OF PROTEINS

Publication No.: US2022252612A1 11/08/2022

Applicant:

HARVARD COLLEGE [US]

US_2015309044_A1

Absstract of: US2022252612A1

Methods for the large scale identification of post-translational modification states of proteins and enzyme activities for carrying out post-translational modification reactions involve the analysis of functional extracts from fresh and frozen samples using protein arrays. The methods and kits of the present invention can be used to analyze and characterize compounds for their effects on post-translational modifications and their pathways. The methods and kits can also be used to diagnose and characterize a wide variety of diseases and medical conditions, including cancer, neurodegenerative diseases, immune diseases, infectious diseases, genetic diseases, metabolic conditions, and drug effects using cells or body fluids of a patient.

traducir

APOLIPOPROTEIN E FRAGMENTS

Publication No.: US2022251171A1 11/08/2022

Applicant:

EISAI R&D MAN CO LTD [JP]
BIOARCTIC AB [SE]

CN_114008072_A

Absstract of: US2022251171A1

The present invention relates to novel fragments of apolipoprotein E (ApoE). These ApoE fragments have a variety of uses including as components of vaccine compositions, particularly vaccines for the prevention or treatment of neurological disorders such as Alzheimer's disease. The ApoE fragments may also be used in screening methods and methods of detection.

traducir

BIOMARKER FOR DIAGNOSIS OF CEREBRAL NERVOUS SYSTEM DISEASES

Publication No.: US2022252618A1 11/08/2022

Applicant:

IND ACADEMIC COOP FOUNDATION YONSEI UNIV [KR]
UNIV INDUSTRY COOP GROUP KYUNG HEE UNIV [KR]

KR_20200141401_A

Absstract of: US2022252618A1

The present invention relates to biomarkers capable of diagnosing various brain and nervous system diseases, and a method of providing information for diagnosing brain and nervous system diseases using the same. According to the present invention, it is possible to diagnose, at an early stage, the onset of a brain and nervous system disease or the likelihood of developing the disease or diagnose the progress or prognosis of the disease or the therapeutic effect against the disease, by measuring the expression level of the biomarker protein of the present invention or a gene encoding the same in the aqueous humor of the eye.

traducir

BLOOD INDICATORS OF ALZHEIMER'S DISEASE

Publication No.: WO2022168006A1 11/08/2022

Applicant:

THE INST FOR ETHNOMEDICINE DBA BRAIN CHEMISTRY LABS [US]

US_2022252620_A1

Absstract of: WO2022168006A1

Presented herein are methods of identifying a subject who has, or is at risk of developing Alzheimer's disease comprising determining a presence or amount of 2-aminoethyl dihydrogen phosphate or taurine in the blood, or a blood product, obtained from the subject. Also presented herein are method of preventing, treating or delaying the onset of Alzheimer's disease.

traducir

TAU IMMUNOTHERAPY

Publication No.: JP2022116136A 09/08/2022

Applicant:

プロセナバイオサイエンシーズリミテッド

US_2021032319_A1

Absstract of: WO2017191559A1

The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

traducir

ANTIBODIES TO PYROGLUTAMATE AMYLOID-β AND USES THEREOF

Publication No.: JP2022115986A 09/08/2022

Applicant:

ヤンセンファーマシューティカエヌ.ベー.

US_2021147528_A1

Absstract of: WO2018083628A1

The invention provides an antibody or antigen binding fragments thereof that binds to 3pE Aβ and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other β-amyloid-related diseases.

traducir

HUMANIZED ANTI-ABETA MONOCLONAL ANTIBODY AND APPLICATION THEREOF

Publication No.: US2022242936A1 04/08/2022

Applicant:

CHANGCHUN GENESCIENCE PHARMACEUTICAL CO LTD [CN]

JP_2022523517_A

Absstract of: US2022242936A1

Provided are a humanized anti-Aβ monoclonal antibody and use thereof. The humanized anti-Aβ monoclonal antibody provided can inhibit the polymerization of Aβ monomers, protect nerve cells from the toxicity of Aβ, and have a certain effect on improving the cognitive learning and memory ability of Alzheimer's dementia model mice, and can be used for the treatment and diagnosis of diseases and disorders related to amyloidosis, such as Alzheimer's disease.

traducir

NEURODEGENERATIVE DISEASE THERAPIES UTILIZING THE SKIN-BRAIN AXIS

Publication No.: US2022244275A1 04/08/2022

Applicant:

OHIO STATE INNOVATION FOUNDATION [US]

CN_114423413_PA

Absstract of: US2022244275A1

As disclosed herein, the skin can dispatch signals to the brain in the form of exosomes, referred to herein as a “skin-brain axis.” Therefore, disclosed herein is a method for diagnosing a brain disease, disorder, or injury in a subject that involves isolating exosomes from the subject and assaying the exosomes for the presence of one or more biomarkers of the disease, disorder, or injury. Also disclosed are methods of treating a subject with a brain disease, disorder, or injury that involves engineering the skin of the subject to produce therapeutic exosomes. Also disclosed are methods of collecting skin-produced exosomes and loading them with therapeutic cargo that can treat one or more diseases, disorders, or injuries of the brain. Also disclosed herein is a method to reduce exosomal release from the skin to reducing trafficking to the brain.

traducir

ANTIBODY DIRECTED AGAINST THE APOE AMINO-TERMINAL FRAGMENT OF 12KDA

Publication No.: US2022242939A1 04/08/2022

Applicant:

BIOARCTIC AB [SE]

KR_20220029653_A

Absstract of: US2022242939A1

The disclosure relates to an antibody or antigen binding portion thereof, which binds to a neo-epitope of a C-terminal fragment of apolipoprotein E, to methods of producing such an antibody or antigen binding portion thereof, and to therapeutic and diagnostic uses thereof.

traducir

HUMANIZED ANTI-ABETA MONOCLONAL ANTIBODY AND APPLICATION THEREOF

Publication No.: US2022242937A1 04/08/2022

Applicant:

CHANGCHUN GENESCIENCE PHARMACEUTICAL CO LTD [CN]

JP_2022523516_A

Absstract of: US2022242937A1

Provided are a humanized anti-Aβ monoclonal antibody and use thereof. The humanized anti-Aβ monoclonal antibody provided can inhibit the polymerization of Aβ monomers, protect nerve cells from the toxicity of Aβ, and have a certain effect on improving the cognitive learning and memory ability of Alzheimer's dementia model mice, and can be used for the treatment and diagnosis of diseases and disorders related to amyloidosis, such as Alzheimer's disease.

traducir

BIOMARKER FOR DIAGNOSIS OF DEMENTIA

Publication No.: WO2022163818A1 04/08/2022

Applicant:

UNIV TOHOKU [JP]

JP_2022116453_A

Absstract of: WO2022163818A1

A method for detecting a neurodegenerative disease in a subject, the method comprising measuring the level of two types of biomarkers including FABP3 and FABP5 in a biological sample from the subject.

traducir

METHOD FOR TREATMENT OF TRAUMATIC BRAIN INJURY TARGETING AGGREGATED PEPTIDES

Publication No.: JP2022113682A 04/08/2022

Applicant:

バイオアークティックアクティエボラーグ

JP_2018522891_A

Absstract of: WO2017013599A1

A method of preventing, alleviating or treating traumatic brain injury in an individual comprises administering to the individual a therapeutically effective and physiologically acceptable amount of an agent capable of reducing the amount of one or more aggregated forms of one or more peptides in the brain. An agent capable of reducing the amount of one or more aggregated forms of one or more peptides in the brain is suitable for use in preventing, alleviating or treating traumatic brain injury. A method for predication of the risk of an individual for complications after a traumatic brain injury comprises detecting one or more aggregated forms of one or more peptides prone to aggregate as a result of a traumatic brain injury event, in the brain of the individual, wherein an increased level of such aggregates in the brain indicates an increased risk for complications.

traducir

COMPOUNDS AND METHODS TARGETING HUMAN TAU

Publication No.: JP2022534759A 03/08/2022

Applicant:

イーライリリーアンドカンパニー

US_2022146535_A1

Absstract of: WO2020242963A1

The present invention provides compounds and methods targeting human tau, particularly human tau phosphorylated at threonine (217) and isoforms of tau expressed only in the CNS, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of neurodegenerative diseases such as AD, PSP and FTD.

traducir

CONFORMATION-SPECIFIC EPITOPES IN TAU, ANTIBODIES THERETO AND METHODS RELATED THEREOF

Publication No.: JP2022534406A 29/07/2022

Applicant:

ザユニヴァーシティオブブリティッシュコロンビア

US_2022218805_A1

Absstract of: WO2020237375A1

The disclosure pertains to conformational epitopes in oligomeric tau, antibodies thereto and methods of making and using immunogens and antibodies specific thereto. The antibodies bind activity neutralizing sites in tau. Also provided are methods for making and using, including methods for treating a tauopathy.

traducir

METHODS FOR DETECTING CSF TAU SPECIES WITH STAGE AND PROGRESSION OF ALZHEIMER DISEASE, AND USE THEREOF

Publication No.: WO2022159766A1 28/07/2022

Applicant:

UNIV WASHINGTON [US]
BATEMAN RANDALL [US]
MCDADE ERIC [US]
BARTHELEMY NICOLAS [US]
HORIE KANTA [US]
LI YAN [US]

Absstract of: WO2022159766A1

The present disclosure provides methods to quantify and analyze various CSF Tau species and the use thereof to measure pathological features and/or clinical symptoms of tauopathies, including determining the amount of time to dementia due to Alzheimer's disease, determining the time from dementia onset, staging Alzheimer's disease, guiding treatment decisions, and evaluate the clinical efficacy of certain therapeutic interventions.

traducir

Methods for Evaluation and Treatment of Alzheimer's Disease and Applications Thereof

Publication No.: US2022236294A1 28/07/2022

Applicant:

HUNTINGTON MEDICAL RES INSTITUTES [US]

CA_3141431_PA

Absstract of: US2022236294A1

Methods to determine risk of Alzheimer's disease and applications thereof are described. Generally, systems and methods utilize analyte measurements, such as dicarboxylic acid levels, to determine a risk of Alzheimer's disease. Based on Alzheimer disease risk, diagnostics or treatments can be performed.

traducir

METHODS OF SCREENING FOR CONDENSATE-ASSOCIATED SPECIFICITY AND USES THEREOF

Nº publicación: EP4031876A1 27/07/2022

Applicant:

DEWPOINT THERAPEUTICS INC [US]

CN_114729941_PA

Absstract of: WO2021055644A1

Methods of identifying a compound, such as a test compound, and applications thereof are provided. For example, methods of identifying a compound that preferentially affects, increases, or decreases a level of association of a macromolecule with one or more target condensates or methods of identifying a compound that preferentially causes a macromolecule to associate or disassociate with one or more target condensates are provided. Additionally, methods of designing and/or identifying and/or making a compound, or portion thereof, with a desired characteristic are provided.

traducir

Page1/3 nextPage results/page

punteroimgGo back